New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
08:05 EDTSLXPSalix price target raised to $150 from $125 at Brean Capital
Brean Capital raised its price target on Salix to $150 from $125 to reflect the tax inversion benefits of its Cosmo acquisition. The firm also cited the addition of patents from Cosmo and positive TARGET 3 data for Xifaxan for use in irritable bowel syndrome and keeps its Buy rating on the stock.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
12:34 EDTSLXPSalix mentioned as a potential acquisition target by dealReporter
November 14, 2014
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:03 EDTSLXPSalix upgraded to Buy from Neutral at UBS
UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use